Authors: JACOBSON MA WULFSOHN M FEINBERG JE DAVIS R POWER M OWENS S CAUSEY D HEATHCHIOZZI ME MURPHY RL CHEUNG TW DIETERICH DT SPECTOR SA MCKINLEY GF PARENTI DM CRUMPACKER C NISHIMOTO B LEEDOM JM KRAMER F COHEN C LOFTUS J KESSLER HA POTTAGE JC BENSON CA PHAIR JP GERITS P CHUSID E SACKS HS FRIEDBERG D CURRANKRIKORIAN K VALENTINE FT MENG TC FREEMAN WR MEIXNER L RICHMAN D ODONNELL JJ KIMBRELL C BOGGIO K LARSON J WHITMORE PV SIMON GL LELACHEUR S FIFE K ZWICKL B RELUE J STEIGBIGEL RT FUHRER J DONLON W BURK RA PORTMORE AC WEISSBACH NE HOOTON TM HOLZWORTH P DAVISON S COLLIER AC POWDERLY WG KLEBERT M ROYAL M SEYFRIED W SQUIRES KC WEISS W BARBACCI M BECKER RL JABS D BARTLETT JG PARA MF JONES M NEIDIG JL FASS RJ VANDERHORST C KYLSTRA J RAASCH R BLOODGOOD K WOLITZ R KIRK S ROLFE L PATRONEREESE J BARTLETT JA WASKIN HA WILLIAMS DK SHIP KW KAHL P ASSAYKEEN T KAROL C MARTINMUNLEY S SUMNER P

Citation: Ma. Jacobson et al., PHASE-II DOSE-RANGING TRIAL OF FOSCARNET SALVAGE THERAPY FOR CYTOMEGALOVIRUS RETINITIS IN AIDS PATIENTS INTOLERANT OF OR RESISTANT TO GANCICLOVIR (ACTG PROTOCOL 093), AIDS, 8(4), 1994, pp. 451-459